source
- Servier to acquire Edgewise's experimental muscular dystrophy drug in $2.7B dealServier, a French pharmaceutical company, announced it will acquire the muscular dystrophy business of Colorado biotech Edgewise Therapeutics. The deal centers on sevasemten, an experimental oral…
- ASCO meeting highlights grief alongside cancer data, honoring late oncologist Amy LinAt the annual American Society of Clinical Oncology meeting, scientists presented abundant new cancer data, but this year the program also gave space to the emotional side of oncology. Outgoing pr…